Real-world safety evaluation of atorvastatin: insights from the US FDA adverse event reporting system (FAERS)

Objective Given the extensive use of atorvastatin in managing cardiovascular conditions and the surge in reported adverse drug reactions (ADRs), this study leverages the FAERS database to comprehensively evaluate atorvastatin-associated adverse events, thereby enhancing our understanding of its safety profile in real-world settings.